[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100261893":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":18,"responsibleParty":35,"collaborators":39,"id":46,"slug":18,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":18,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":18,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":18,"overallStatus":65,"whyStopped":18,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":18},{"fullName":5,"class":6},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"A (Intervention group,sunitinib)","EXPERIMENTAL","Beginning 4-12 weeks following radical nephrectomy, patients receive sunitinib malate PO QD for 4 weeks",[13],"Drug: sunitinib",{"label":15,"type":16,"description":17,"interventionNames":18},"B(observation group)","NO_INTERVENTION","Patients with radical nephrectomy are observed without intervention",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","sunitinib","The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.",[9],[26],{"name":27,"affiliation":5,"role":28},"Jun-Hang Luo, MD","STUDY_DIRECTOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},"Jinhuan Wei, MD","CONTACT","+8613580314021","342729243@qq.com",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Jun-Hang Luo","Professor",[40,42,44],{"name":41,"class":6},"Xi'an Jiaotong University",{"name":43,"class":6},"Yantai Yuhuangding Hospital",{"name":45,"class":6},"Sun Yat-sen University","100261893",false,"NCT02688491","A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment","A Multi-site, Open, Perspective Study of Prognostic Value and Benefit From Adjuvant Targeted Therapy of Stage III Clear Cell Renal Cell Carcinoma Based on a CpG-methylation-based Assay","Inclusion Criteria:\n\n* The informed consent has been obtained from the patient.\n* With confirmed diagnosis of stage III clear cell renal cell carcinoma\n* With moderate\u002Fgood ECOG health rating (PS): 0-1 score.\n* The patient receive no anti-cancer treatment before primary surgery.\n* The patient receive radical operation for renal cancer with negative margin.\n\nExclusion Criteria:\n\n* With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.\n* With bad compliance or contraindication to enrollment.\n* Pregnant woman or lactating woman.\n* With contraindication to receive adjuvant targeted therapy.","ALL","18 Years","75 Years",{"count":56,"type":57},300,"ESTIMATED","INTERVENTIONAL",[60],"NA","Whether patients with stage III clear cell renal cell carcinoma(ccRCC) should receive adjuvant targeted therapy or not is still on debate. The investigators invented a assay consisting of 5 CpGs: cg00396667（PITX1）, cg18815943 （FOXE3）, cg03890877（TWF2）, cg07611000 （EHBP1L1）and cg14391855（RIN1）that was successfully categorise patients with stage III clear cell renal cell carcinoma into high-risk and low-risk groups with Harzard Ratio(HR) of 4.93. Here the investigators randomly assign assay-defined high risk patients of locally advanced ccRCC into adjuvant targeted therapy group and observation group.Disease free survival and overall survival are the end points of observation.",[63,64],"Renal Neoplasms","Targeted Molecular Therapy","NOT_YET_RECRUITING","2016-02-24",{"date":68,"type":57},"2016-02-25",{"date":70,"type":18},"2016-07",{"date":72,"type":57},"2026-07",{"name":5,"class":6}]